BioLineRX Ltd

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs fr...

BioLineRx reported Q1 2026 results with a net loss of $2.6 million versus net income of $5.1 million in Q1 2025. The company initiated a Phase I/IIa trial for GLIX1 in glioblastoma with first patient dosed at NYU Langone Health, supported by preclinical data showing dose-dependent tumor growth inhibition. APHEXDA royalty revenues increased to $0....

BioLineRx, a commercial-stage biopharmaceutical company, announced that it will release its Q3 2024 financial results on November 25, 2024, and host a conference call the same day.

HC Wainwright & Co. has decided to maintain its Buy rating of BioLine Rx (NASDAQ:BLRX) and raise its price target from $19.00 to $21.00. Shares of BioLine Rx are trading up 11.36% over the last 24 hours, at $1.96 per share. A move to $21.00 would account for a 971.43% increase from the current share price. About BioLine Rx BioLine Rx Ltd is a pre...

B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to close at $35.71 on Thursday. Truist Securities boosted Vornado Realty Trust (NYSE: VNO) price target from $22 to $27. Truist Securities analyst ...